Global Drug-Resistant Tuberculosis Treatment Market growth is projected to reach USD $ Billion in 2025, at a $% CAGR by driving industry size, share, segments research, top company analysis, trends and forecast report 2025 to 2031.

Global Drug-Resistant Tuberculosis Treatment Market Growth and Outlook 2025-31

The global Drug-Resistant Tuberculosis Treatment market size is predicted to grow from US$ 2383 million in 2025 to US$ 3286 million in 2031; it is expected to grow at a CAGR of 5.5% from 2025 to 2031. Drug-resistant tuberculosis (DR-TB) treatment refers to the medical interventions and therapies used to manage and combat tuberculosis (TB) infections caused by strains of the Mycobacterium tuberculosis bacteria that are resistant to one or more of the standard anti-TB drugs. DR-TB is a significant global health concern because it poses challenges for effective TB control and requires more complex and prolonged treatment regimens compared to drug-susceptible TB. There are different categories of DR-TB, including multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), each with its own treatment protocols. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Infinity Market Research newest research report, the ?Drug-Resistant Tuberculosis Treatment Industry Forecast? looks at past sales and reviews total world Drug-Resistant Tuberculosis Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Drug-Resistant Tuberculosis Treatment sales for 2025 through 2031. With Drug-Resistant Tuberculosis Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Drug-Resistant Tuberculosis Treatment industry. This Insight Report provides a comprehensive analysis of the global Drug-Resistant Tuberculosis Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Drug-Resistant Tuberculosis Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Drug-Resistant Tuberculosis Treatment market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Drug-Resistant Tuberculosis Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Drug-Resistant Tuberculosis Treatment. This report presents a comprehensive overview, market shares, and growth opportunities of Drug-Resistant Tuberculosis Treatment market by product type, application, key players and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; First-Line Anti-TB Drugs &nbsp;&nbsp;&nbsp; Second-Line Anti-TB Drugs &nbsp;&nbsp;&nbsp; Others Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospital Pharmacy &nbsp;&nbsp;&nbsp; Online Pharmacy &nbsp;&nbsp;&nbsp; Retail Pharmacy &nbsp;&nbsp;&nbsp; Others This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Sanofi &nbsp;&nbsp;&nbsp; Novartis AG &nbsp;&nbsp;&nbsp; Endo International plc &nbsp;&nbsp;&nbsp; CMP Pharma &nbsp;&nbsp;&nbsp; STI Pharma LLC &nbsp;&nbsp;&nbsp; Akorn Incorporated &nbsp;&nbsp;&nbsp; Lupin &nbsp;&nbsp;&nbsp; Johnson & Johnson Services Inc. &nbsp;&nbsp;&nbsp; Macleods Pharmaceuticals Ltd &nbsp;&nbsp;&nbsp; Pfizer Inc &nbsp;&nbsp;&nbsp; Hikma Pharmaceuticals PLC &nbsp;&nbsp;&nbsp; Lannett &nbsp;&nbsp;&nbsp; Mylan N.V. &nbsp;&nbsp;&nbsp; Teva Pharmaceutical Industries Ltd &nbsp;&nbsp;&nbsp; Fresenius Kabi AG

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Drug-Resistant Tuberculosis Treatment Market Size (2020-2031) &nbsp;2.1.2 Drug-Resistant Tuberculosis Treatment Market Size CAGR by Region (2020 VS 2024 VS 2031) &nbsp;2.1.3 World Current & Future Analysis for Drug-Resistant Tuberculosis Treatment by Country/Region (2020, 2024 & 2031) &nbsp;2.2 Drug-Resistant Tuberculosis Treatment Segment by Type &nbsp;2.2.1 First-Line Anti-TB Drugs &nbsp;2.2.2 Second-Line Anti-TB Drugs &nbsp;2.2.3 Others &nbsp;2.3 Drug-Resistant Tuberculosis Treatment Market Size by Type &nbsp;2.3.1 Drug-Resistant Tuberculosis Treatment Market Size CAGR by Type (2020 VS 2024 VS 2031) &nbsp;2.3.2 Global Drug-Resistant Tuberculosis Treatment Market Size Market Share by Type (2020-2025) &nbsp;2.4 Drug-Resistant Tuberculosis Treatment Segment by Application &nbsp;2.4.1 Hospital Pharmacy &nbsp;2.4.2 Online Pharmacy &nbsp;2.4.3 Retail Pharmacy &nbsp;2.4.4 Others &nbsp;2.5 Drug-Resistant Tuberculosis Treatment Market Size by Application &nbsp;2.5.1 Drug-Resistant Tuberculosis Treatment Market Size CAGR by Application (2020 VS 2024 VS 2031) &nbsp;2.5.2 Global Drug-Resistant Tuberculosis Treatment Market Size Market Share by Application (2020-2025) 3 Drug-Resistant Tuberculosis Treatment Market Size by Player &nbsp;3.1 Drug-Resistant Tuberculosis Treatment Market Size Market Share by Player &nbsp;3.1.1 Global Drug-Resistant Tuberculosis Treatment Revenue by Player (2020-2025) &nbsp;3.1.2 Global Drug-Resistant Tuberculosis Treatment Revenue Market Share by Player (2020-2025) &nbsp;3.2 Global Drug-Resistant Tuberculosis Treatment Key Players Head office and Products Offered &nbsp;3.3 Market Concentration Rate Analysis &nbsp;3.3.1 Competition Landscape Analysis &nbsp;3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.4 New Products and Potential Entrants &nbsp;3.5 Mergers & Acquisitions, Expansion 4 Drug-Resistant Tuberculosis Treatment by Region &nbsp;4.1 Drug-Resistant Tuberculosis Treatment Market Size by Region (2020-2025) &nbsp;4.2 Global Drug-Resistant Tuberculosis Treatment Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Drug-Resistant Tuberculosis Treatment Market Size Growth (2020-2025) &nbsp;4.4 APAC Drug-Resistant Tuberculosis Treatment Market Size Growth (2020-2025) &nbsp;4.5 Europe Drug-Resistant Tuberculosis Treatment Market Size Growth (2020-2025) &nbsp;4.6 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size Growth (2020-2025) 5 Americas &nbsp;5.1 Americas Drug-Resistant Tuberculosis Treatment Market Size by Country (2020-2025) &nbsp;5.2 Americas Drug-Resistant Tuberculosis Treatment Market Size by Type (2020-2025) &nbsp;5.3 Americas Drug-Resistant Tuberculosis Treatment Market Size by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Drug-Resistant Tuberculosis Treatment Market Size by Region (2020-2025) &nbsp;6.2 APAC Drug-Resistant Tuberculosis Treatment Market Size by Type (2020-2025) &nbsp;6.3 APAC Drug-Resistant Tuberculosis Treatment Market Size by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia 7 Europe &nbsp;7.1 Europe Drug-Resistant Tuberculosis Treatment Market Size by Country (2020-2025) &nbsp;7.2 Europe Drug-Resistant Tuberculosis Treatment Market Size by Type (2020-2025) &nbsp;7.3 Europe Drug-Resistant Tuberculosis Treatment Market Size by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Drug-Resistant Tuberculosis Treatment by Region (2020-2025) &nbsp;8.2 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size by Type (2020-2025) &nbsp;8.3 Middle East & Africa Drug-Resistant Tuberculosis Treatment Market Size by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Global Drug-Resistant Tuberculosis Treatment Market Forecast &nbsp;10.1 Global Drug-Resistant Tuberculosis Treatment Forecast by Region (2026-2031) &nbsp;10.1.1 Global Drug-Resistant Tuberculosis Treatment Forecast by Region (2026-2031) &nbsp;10.1.2 Americas Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.1.3 APAC Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.1.4 Europe Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.1.5 Middle East & Africa Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.2 Americas Drug-Resistant Tuberculosis Treatment Forecast by Country (2026-2031) &nbsp;10.2.1 United States Market Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.2.2 Canada Market Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.2.3 Mexico Market Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.2.4 Brazil Market Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.3 APAC Drug-Resistant Tuberculosis Treatment Forecast by Region (2026-2031) &nbsp;10.3.1 China Drug-Resistant Tuberculosis Treatment Market Forecast &nbsp;10.3.2 Japan Market Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.3.3 Korea Market Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.3.4 Southeast Asia Market Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.3.5 India Market Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.3.6 Australia Market Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.4 Europe Drug-Resistant Tuberculosis Treatment Forecast by Country (2026-2031) &nbsp;10.4.1 Germany Market Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.4.2 France Market Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.4.3 UK Market Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.4.4 Italy Market Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.4.5 Russia Market Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.5 Middle East & Africa Drug-Resistant Tuberculosis Treatment Forecast by Region (2026-2031) &nbsp;10.5.1 Egypt Market Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.5.2 South Africa Market Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.5.3 Israel Market Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.5.4 Turkey Market Drug-Resistant Tuberculosis Treatment Forecast &nbsp;10.6 Global Drug-Resistant Tuberculosis Treatment Forecast by Type (2026-2031) &nbsp;10.7 Global Drug-Resistant Tuberculosis Treatment Forecast by Application (2026-2031) &nbsp;10.7.1 GCC Countries Market Drug-Resistant Tuberculosis Treatment Forecast 11 Key Players Analysis &nbsp;11.1 Sanofi &nbsp;11.1.1 Sanofi Company Information &nbsp;11.1.2 Sanofi Drug-Resistant Tuberculosis Treatment Product Offered &nbsp;11.1.3 Sanofi Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.1.4 Sanofi Main Business Overview &nbsp;11.1.5 Sanofi Latest Developments &nbsp;11.2 Novartis AG &nbsp;11.2.1 Novartis AG Company Information &nbsp;11.2.2 Novartis AG Drug-Resistant Tuberculosis Treatment Product Offered &nbsp;11.2.3 Novartis AG Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.2.4 Novartis AG Main Business Overview &nbsp;11.2.5 Novartis AG Latest Developments &nbsp;11.3 Endo International plc &nbsp;11.3.1 Endo International plc Company Information &nbsp;11.3.2 Endo International plc Drug-Resistant Tuberculosis Treatment Product Offered &nbsp;11.3.3 Endo International plc Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.3.4 Endo International plc Main Business Overview &nbsp;11.3.5 Endo International plc Latest Developments &nbsp;11.4 CMP Pharma &nbsp;11.4.1 CMP Pharma Company Information &nbsp;11.4.2 CMP Pharma Drug-Resistant Tuberculosis Treatment Product Offered &nbsp;11.4.3 CMP Pharma Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.4.4 CMP Pharma Main Business Overview &nbsp;11.4.5 CMP Pharma Latest Developments &nbsp;11.5 STI Pharma LLC &nbsp;11.5.1 STI Pharma LLC Company Information &nbsp;11.5.2 STI Pharma LLC Drug-Resistant Tuberculosis Treatment Product Offered &nbsp;11.5.3 STI Pharma LLC Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.5.4 STI Pharma LLC Main Business Overview &nbsp;11.5.5 STI Pharma LLC Latest Developments &nbsp;11.6 Akorn Incorporated &nbsp;11.6.1 Akorn Incorporated Company Information &nbsp;11.6.2 Akorn Incorporated Drug-Resistant Tuberculosis Treatment Product Offered &nbsp;11.6.3 Akorn Incorporated Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.6.4 Akorn Incorporated Main Business Overview &nbsp;11.6.5 Akorn Incorporated Latest Developments &nbsp;11.7 Lupin &nbsp;11.7.1 Lupin Company Information &nbsp;11.7.2 Lupin Drug-Resistant Tuberculosis Treatment Product Offered &nbsp;11.7.3 Lupin Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.7.4 Lupin Main Business Overview &nbsp;11.7.5 Lupin Latest Developments &nbsp;11.8 Johnson & Johnson Services Inc. &nbsp;11.8.1 Johnson & Johnson Services Inc. Company Information &nbsp;11.8.2 Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Product Offered &nbsp;11.8.3 Johnson & Johnson Services Inc. Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.8.4 Johnson & Johnson Services Inc. Main Business Overview &nbsp;11.8.5 Johnson & Johnson Services Inc. Latest Developments &nbsp;11.9 Macleods Pharmaceuticals Ltd &nbsp;11.9.1 Macleods Pharmaceuticals Ltd Company Information &nbsp;11.9.2 Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Product Offered &nbsp;11.9.3 Macleods Pharmaceuticals Ltd Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.9.4 Macleods Pharmaceuticals Ltd Main Business Overview &nbsp;11.9.5 Macleods Pharmaceuticals Ltd Latest Developments &nbsp;11.10 Pfizer Inc &nbsp;11.10.1 Pfizer Inc Company Information &nbsp;11.10.2 Pfizer Inc Drug-Resistant Tuberculosis Treatment Product Offered &nbsp;11.10.3 Pfizer Inc Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.10.4 Pfizer Inc Main Business Overview &nbsp;11.10.5 Pfizer Inc Latest Developments &nbsp;11.11 Hikma Pharmaceuticals PLC &nbsp;11.11.1 Hikma Pharmaceuticals PLC Company Information &nbsp;11.11.2 Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Product Offered &nbsp;11.11.3 Hikma Pharmaceuticals PLC Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.11.4 Hikma Pharmaceuticals PLC Main Business Overview &nbsp;11.11.5 Hikma Pharmaceuticals PLC Latest Developments &nbsp;11.12 Lannett &nbsp;11.12.1 Lannett Company Information &nbsp;11.12.2 Lannett Drug-Resistant Tuberculosis Treatment Product Offered &nbsp;11.12.3 Lannett Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.12.4 Lannett Main Business Overview &nbsp;11.12.5 Lannett Latest Developments &nbsp;11.13 Mylan N.V. &nbsp;11.13.1 Mylan N.V. Company Information &nbsp;11.13.2 Mylan N.V. Drug-Resistant Tuberculosis Treatment Product Offered &nbsp;11.13.3 Mylan N.V. Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.13.4 Mylan N.V. Main Business Overview &nbsp;11.13.5 Mylan N.V. Latest Developments &nbsp;11.14 Teva Pharmaceutical Industries Ltd &nbsp;11.14.1 Teva Pharmaceutical Industries Ltd Company Information &nbsp;11.14.2 Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Product Offered &nbsp;11.14.3 Teva Pharmaceutical Industries Ltd Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.14.4 Teva Pharmaceutical Industries Ltd Main Business Overview &nbsp;11.14.5 Teva Pharmaceutical Industries Ltd Latest Developments &nbsp;11.15 Fresenius Kabi AG &nbsp;11.15.1 Fresenius Kabi AG Company Information &nbsp;11.15.2 Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Product Offered &nbsp;11.15.3 Fresenius Kabi AG Drug-Resistant Tuberculosis Treatment Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.15.4 Fresenius Kabi AG Main Business Overview &nbsp;11.15.5 Fresenius Kabi AG Latest Developments 12 Research Findings and Conclusion

Report	Global Drug-Resistant Tuberculosis Treatment Market Growth (Status and Outlook) 2025-2031
Selected License	Multi ID: LPI7114

Buyer Information

Order Summary